PE20041063A1 - Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico - Google Patents

Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Info

Publication number
PE20041063A1
PE20041063A1 PE2004000262A PE2004000262A PE20041063A1 PE 20041063 A1 PE20041063 A1 PE 20041063A1 PE 2004000262 A PE2004000262 A PE 2004000262A PE 2004000262 A PE2004000262 A PE 2004000262A PE 20041063 A1 PE20041063 A1 PE 20041063A1
Authority
PE
Peru
Prior art keywords
formulation
chloro
methyl
fluoroaniline
pharmaceutical composition
Prior art date
Application number
PE2004000262A
Other languages
English (en)
Inventor
Patrick Forenzo
Maha Y Khaled
Barbara Wang
Joseph Lawrence Zielinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20041063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20041063A1 publication Critical patent/PE20041063A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION ORAL LIQUIDA QUE COMPRENDE a) AGUA; b) ACIDO 5-METIL-2-(2'-CLORO-6'-FLUOROANILINO)FENILACETICO Y c) UN AGENTE DE SUSPENSION SELECCIONADO DE CELULOSA MICROCRISTALINA, CARBOXIMETILCELULOSA DE SODIO, GOMA XANTAN, ENTRE OTROS; DONDE EL pH DE LA FORMULACION ES DE 4.3 A 5.5. LA FORMULACION COMPRENDE ADEMAS UN HUMECTANTE SELECCIONADO DE POLISORBATO 80, POLAXAMEROS, ACEITE DE RICINO, ENTRE OTROS; UN AGENTE ANTIESPUMANTE; UN CONSERVADOR. LA FORMULACION COMPRENDE UN SISTEMA REGULADOR DE pH QUE COMPRENDE CITRATO DE METAL ALCALINO CON ACIDO CITRICO, SALES DE ACETATO, SALES DE SUCCINATO ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION
PE2004000262A 2003-03-12 2004-03-10 Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico PE20041063A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
PE20041063A1 true PE20041063A1 (es) 2005-03-07

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000262A PE20041063A1 (es) 2003-03-12 2004-03-10 Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Country Status (30)

Country Link
US (2) US20060094787A1 (es)
EP (1) EP1603550B1 (es)
JP (1) JP4580921B2 (es)
KR (1) KR20050109077A (es)
CN (1) CN100345536C (es)
AR (1) AR043536A1 (es)
AT (1) ATE418332T1 (es)
AU (1) AU2004218921B2 (es)
BR (1) BRPI0408270A (es)
CA (1) CA2518393A1 (es)
CL (1) CL2004000496A1 (es)
DE (1) DE602004018622D1 (es)
EC (1) ECSP055998A (es)
ES (1) ES2318277T3 (es)
HK (1) HK1086492A1 (es)
HR (1) HRP20050787A2 (es)
IL (1) IL170518A (es)
IS (1) IS2658B (es)
MA (1) MA27670A1 (es)
MX (1) MXPA05009686A (es)
MY (1) MY139455A (es)
NO (1) NO20054662L (es)
NZ (1) NZ542218A (es)
PE (1) PE20041063A1 (es)
PT (1) PT1603550E (es)
RU (1) RU2363462C2 (es)
TN (1) TNSN05222A1 (es)
TW (1) TWI327913B (es)
WO (1) WO2004080451A1 (es)
ZA (1) ZA200506750B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1673079A1 (en) * 2003-10-08 2006-06-28 Novartis AG Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
CN101854913A (zh) * 2007-11-12 2010-10-06 诺瓦提斯公司 含有缬沙坦的液体组合物
EP2926810A1 (en) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
CN109906079B (zh) * 2016-06-16 2022-09-30 库蒂斯制药公司 用于质子泵抑制剂混悬剂的组合物和方法
US20190282500A1 (en) * 2016-09-09 2019-09-19 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF TREATING GLIOBLASTOMA
WO2019067991A1 (en) * 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
MXPA04006608A (es) * 2002-01-07 2004-10-04 Pharmacia Corp Tratamiento de dolor, inflamacion y trastornos relacionados con inflamacion con una combinacion de inhibidor selectivo de ciclooxigenasa-2 y aspirina.
CA2480832A1 (en) * 2002-04-05 2003-10-23 Nitromed, Inc. Nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
MXPA05009686A (es) 2005-10-20
TW200505429A (en) 2005-02-16
RU2363462C2 (ru) 2009-08-10
ES2318277T3 (es) 2009-05-01
TNSN05222A1 (en) 2007-06-11
WO2004080451A1 (en) 2004-09-23
EP1603550B1 (en) 2008-12-24
IS8049A (is) 2005-09-28
CL2004000496A1 (es) 2005-01-14
NO20054662D0 (no) 2005-10-11
US20060094787A1 (en) 2006-05-04
JP2006519811A (ja) 2006-08-31
TWI327913B (en) 2010-08-01
NO20054662L (no) 2005-12-05
IL170518A (en) 2010-11-30
KR20050109077A (ko) 2005-11-17
HRP20050787A2 (en) 2006-12-31
IS2658B (is) 2010-08-15
CA2518393A1 (en) 2004-09-23
ECSP055998A (es) 2006-01-27
CN1756541A (zh) 2006-04-05
HK1086492A1 (en) 2006-09-22
CN100345536C (zh) 2007-10-31
DE602004018622D1 (de) 2009-02-05
AU2004218921A1 (en) 2004-09-23
ZA200506750B (en) 2007-02-28
MA27670A1 (fr) 2005-12-01
ATE418332T1 (de) 2009-01-15
JP4580921B2 (ja) 2010-11-17
PT1603550E (pt) 2009-03-20
AR043536A1 (es) 2005-08-03
BRPI0408270A (pt) 2006-03-07
US20090048344A1 (en) 2009-02-19
EP1603550A1 (en) 2005-12-14
NZ542218A (en) 2009-01-31
RU2005131310A (ru) 2006-05-10
MY139455A (en) 2009-10-30
AU2004218921B2 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
PE20041063A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico
AR102101A2 (es) Formulación y método de complejo de aripiprazol
HRP20170677T1 (hr) Farmaceutski sastav za kontrolirano otpuštanje koji sadrži ester fumarne kiseline
DK1073415T3 (da) Gelerbare farmaceutiske sammensætninger
ES2102919T3 (es) Composicion acida a base de vesiculas lipidicas y su utilizacion en aplicacion topica
NO20002991D0 (no) Farmasøytiske sammensetninger som inneholder en omega-3- fettsyreolje
BE901359A (fr) Composition pharmaceutique a absorption reglee.
TNSN04023A1 (fr) Formulation de suspension orale stabilisee
CO5170479A1 (es) Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado saturado y un mono de ester de acido acrilico. .
BRPI0409345A (pt) sistema de liberação, pelìcula de sistema de liberação, e, processo para preparar o sistema de pelìcula de gel homogêneo
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
NO20010863D0 (no) Nye orale formuleringer for 5-HT4-agonister eller - antagonister
RU2002103315A (ru) Офтальмическая композиция, содержащая кетотифен
BRPI0517245A (pt) suspensão farmacêutica e de acetaminofeno isentas de corantes
PE20130180A1 (es) Soluciones farmaceuticas orales que comprenden telbivudina
JP4880813B2 (ja) 外用消炎鎮痛剤組成物
AR030630A1 (es) Composiciones farmaceuticas
ATE245968T1 (de) Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung
CL2012001545A1 (es) Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras.
ES2052075T3 (es) Composicion farmaceutica liquida para derivados de piperidinoalcanol.
TH77904A (th) สารผสมทางเภสัชกรรม
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
BR9907166A (pt) Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina
TH77904B (th) สารผสมทางเภสัชกรรม
KR920703501A (ko) 세바스산 및 그 유도체의 장 경우 영양 및 비경구적 영양에서의 용도 및 이들 화합물을 함유한 의약 조성물

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed